Research Paper Volume 12, Issue 17 pp 17694—17712

Figure 2. Acquired Doc-resistance increases DocRPC cells development of Enz-resistance after two months of Enz treatment. (A) DocS1_CWR22Rv1 (left) and DocR1_CWR22Rv1 (middle) cells were cultured with DMSO for 2 months and then assayed for Enz sensitivity after treated with/without 20 μM Enz for 2, 4 and 6 days. DocR1_CWR22Rv1 cells have slightly less Enz sensitivity (47% vs 54%) compared to DocS1_CWR22Rv1 cells. (B) DocS1_CWR22Rv1 (left) and DocR1_CWR22Rv1 (middle) cells were continually cultured with 20 μM Enz for 2 months, and the cell growth was examined after treating with/without Enz for 0, 2, 4 and 6 days. DocR1_CWR22Rv1 cells have much less Enz sensitivity (from 60% to 1%) compared to DocS1_CWR22Rv1 cells. (C) DocS3_C4-2 (left) and DocR3_C4-2 (middle) cells were cultured with DMSO for 2 months and then were assayed for Enz sensitivity after treating with/without DMSO/Enz for 2, 4 and 6 days. DocR3-C4-2 cells have similar Enz sensitivity (37% vs 47%) compared to DocS3_C4-2. (D) DocS3_C4-2 (left) and DocR3_C4-2 (middle) were continually cultured with 20 μM Enz for 2 months, and the cell growth was examined after treating with/without Enz for 0, 2, 4 and 6 days. DocR3_C4-2 have less Enz sensitivity (from 38% to 4%) comparing with DocS3_C4-2. For A-D the survival rates of 10 μM Enz/DMSO at day 6 are shown in right panels. Results are mean ± SD compared to controls *p<0.05; **p<0.01.